SNPMiner Trials: SNP Report
Report for SNP rs731236
 Developed by Shray Alag, 2019.
SNP Clinical Trial Gene 
There is one clinical trial. 
Clinical Trials
      The link between metabolic disturbances and vitamin D receptor (VDR) and MEGALIN (or LRP2)
      gene polymorphisms remains unclear, particularly among African-American adults. The
      associations of single nucleotide polymorphisms (SNPs) for VDR [rs1544410(BsmI:G/A),
      rs7975232(ApaI:A/C), rs731236(TaqI:G/A)] and MEGALIN [rs3755166:G/A,rs2075252:C/T,
      rs2228171:C/T] genes with incident and prevalent metabolic disturbances, including obesity,
      central obesity and metabolic syndrome (MetS) were evaluated.
      From 1,024 African-Americans participating in the Healthy Aging in Neighborhoods of Diversity
      across the Life Span (HANDLS, Baltimore, MD, 2004-2013) study, 539 subjects were selected who
      had complete genetic data as well as covariates selected for metabolic outcomes at two
      consecutive examinations (visits 1 and 2) with a mean follow-up time of 4.64±0.93y. Haplotype
      (HAP) analyses generated polymorphism groups that were linked to incident and prevalent
      metabolic disturbances.
    
The
      associations of single nucleotide polymorphisms (SNPs) for VDR [rs1544410(BsmI:G/A),
      rs7975232(ApaI:A/C), rs731236(TaqI:G/A)] and MEGALIN [rs3755166:G/A,rs2075252:C/T,
      rs2228171:C/T] genes with incident and prevalent metabolic disturbances, including obesity,
      central obesity and metabolic syndrome (MetS) were evaluated.
  Primary Outcomes 
 Description: Obesity was defined as BMI≥30 kg/m2.
 Measure: Obesity
 Time: 2004-2013
 Description: Central obesity was defined based on waist circumference (WC) ≥ 102 cm or 40 inches (men), ≥ 88 cm or 35 inches (women)
 Measure: Central Obesity
 Time: 2004-2013
 Description: Participants who screened positive on at least 3 of 5 conditions ((1) central obesity (see above); (2) dyslipidemia: TAG≥1.695 mmol/L (150 mg/dl); (3) dyslipidemia: HDL-C<40 mg/dL (male), <50 mg/dL (female); (4) blood pressure≥130/85 mmHg; (5) fasting plasma glucose≥6.1 mmol/L (110 mg/dl).(39)) were classified as MetS-positive (2) Similarly, continuous annual rates of change (Δ) in metabolic outcomes were considered, specifically number of metabolic disturbances (MetD), BMI, WC, SBP, DBP, TAG, HDL-C, and Glucose. Binary incident outcomes included obesity, central obesity, MetS and other metabolic disturbance (i.e. hypertension, dyslipidemia-TAG, dyslipidemia-HDL and hyperglycemia).
 Measure: Metabolic Syndrome
 Time: 2004-2013
HPO Nodes
Obesity 
Genes 318
MYT1L  SOX2  MKRN3  PCSK1  SOX3  MKKS  RAB23  GABRD  SNORD115-1  SPATA7  SOX10  CERKL  PRPF31  LRAT  IFT140  ARL2BP  PNKP  MAK  CNNM2  AHI1  ABCA4  PDE4D  ZBTB20  PDE6A  PDE6G  IMPDH1  HDAC4  CEL  ATRX  TRAF3IP1  PDE6B  PDSS1  CYP7A1  INS  HLA-DQB1  IFT172  KIZ  CDHR1  SMC1A  HLA-DRB1  CYP19A1  RPS6KA3  SDCCAG8  IQSEC2  DHX38  APC2  HDAC8  MC4R  GATA4  PDX1  IPW  BBS1  PWRN1  BBS2  CDH23  BBS4  DHDDS  SRY  NDN  PRPF6  GCK  PSMD12  WNT4  AGBL5  DCC  RREB1  PTEN  HNF4A  SLC10A7  TRIP12  BBS9  TUB  MECP2  BDNF  SNORD116-1  HESX1  FGF17  MKS1  TULP1  HIRA  TNFSF4  BLK  GHR  SEMA3A  XYLT1  ARL6  TTC8  PROM1  BPTF  NEK2  ZDHHC15  ANOS1  SAG  NEUROD1  KIDINS220  KISS1R  PNPLA6  ALMS1  BRAF  PROKR2  CANT1  KLHL7  REEP6  UBE3A  FAM161A  ABCC8  HS6ST1  RBMX  KCNJ11  MCM3AP  SYNE2  UFD1  HACE1  ARNT2  ARL13B  NPAP1  SCAPER  FSCN2  AHR  PRCD  KMT2A  FGF8  AKT2  FGFR1  FGFR3  TACR3  FLRT3  GNAS  HSD11B1  PWAR1  SEMA4A  HERC2  MERTK  FTO  PRMT7  FHL1  USH2A  CLRN1  CNGB1  CNGA1  KDM6A  NIPBL  NR0B2  PHIP  TRAPPC9  TBX1  MOG  CA4  IMPG2  PDE11A  GP1BB  RAD21  CUL4B  PROK2  NPHP1  FLII  CACNA1S  IFT27  GNAS-AS1  KLF11  DPYD  TBX3  HNF1A  BEST1  NR2E3  RAP1A  RAP1B  MAGEL2  DEAF1  FMR1  COMT  OFD1  WDR34  SLC25A4  NRL  CLIP2  IFT74  RNPC3  INPP5E  SYNE1  NTRK2  DUSP6  LZTFL1  CEP290  RBP3  HGSNAT  KCNAB2  WT1  BBIP1  POMC  NSD1  KIAA1549  PHF6  BAZ1B  RDH12  POMGNT1  PRPH2  SHOX  ARHGEF18  PCARE  POU3F4  SPG11  CHD7  TMEM43  SIN3A  AIP  BBS5  H6PD  HUWE1  APOE  IDH3B  PPARG  SIM1  RFC2  XRCC4  SLC7A7  GTF2IRD1  SKI  PRPF8  ADNP  THOC2  CCDC141  CREBBP  RGR  ZNF365  SLC7A14  JMJD1C  SHANK3  LEP  WDPCP  LEPR  CEP164  SH2B1  RHO  CRB1  KIF7  BBS10  MKRN3-AS1  MTFMT  CRX  ZNF711  RLBP1  USP8  MLXIPL  LIMK1  SETD2  EYS  ARL3  KMT2D  IGF1  LIPE  OTX2  IGF1R  GTF2I  IGFALS  NSMF  EGF  SEC24C  LMNA  MEGF8  GUCA1B  IFT88  ARVCF  WDR11  SMC3  PRPF4  FEZF1  P2RY11  PRPF3  SETD5  TRIM32  BBS7  ATP6AP2  EIF2S3  ZNF408  ARMC5  SPRY4  DYRK1B  EHMT1  PRKAR1A  APPL1  FOXP1  ROM1  RP9  RP1  ELN  PAX4  RP2  RPGR  PAX6  RERE  EMD  CTNNB1  C8ORF37  KCNJ18  LAS1L  TOPORS  STX16  IL17RD  ERMARD  CTSH  PRDM16  BBS12  RPE65  SNRNP200  SNRPN  TBL2  EP300  VPS13B  HCRT  AFF4  MAN1B1  RAI1  CEP19  SMAD4  GABRA3  PCNT  ZNF513   hr>
Truncal obesity 
Genes 41
MC4R  GHR  PCSK1  POMC  XYLT1  PRKAR1A  PHF6  CDH23  KMT2A  BPTF  USP8  AKT2  PSMD12  IGF1  IGF1R  ZBTB20  GNAS  IGFALS  FMR1  XRCC4  LAS1L  SLC7A7  ALMS1  THOC2  SLC10A7  SMC3  SETD5  CREBBP  NIPBL  RNPC3  INPP5E  TRAPPC9  EP300  VPS13B  SMC1A  ARMC5  PDE11A  PCNT  DYRK1B  RAD21  HDAC8   hr>